收藏切换
Analysis of Data Monitoring Committee applications in cardiovascular drug development in China
收藏切换
Yafei CHEN, Yu ZHENG, Pengbo LI, Jun LIU, Ya'nan YU*, Zhong WANG*
World Clinical Drug | 2025, 46(4) : 323 - 331
Less
收藏切换
World Clinical Drug | 2025, 46(4): 323-331
• Topic •
Analysis of Data Monitoring Committee applications in cardiovascular drug development in China
Full
Yafei CHEN, Yu ZHENG, Pengbo LI, Jun LIU, Ya'nan YU*, Zhong WANG*
Affiliations
  • Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China
Published: 2025-04-10 doi: 10.13683/j.wph.2025.04.002
Outline
收藏切换
Objective

To systematically analyze the current application status and characteristics of data monitoring committee (DMC) in clinical trials of cardiovascular drug development in China, and to provide reference for optimizing DMC application in clinical trials.

Methods

The clinical trial data of cardiovascular diseases registered from January 2013 to December 1, 2024 were collected from the Drug Clinical Trial Registration and Information Disclosure Platform.Descriptive analysis was conducted to analyze the application of DMC in different trial characteristics (trial status, research scope, study phase, design type, and indications).

Results

A total of 1 917 clinical trials were included, of which 192 (10.01%) implemented DMC. The DMC application rate in international multicenter trials (76.98%) was significantly higher than that in domestic trials (4.18%). The DMC application rate was relatively high in phase Ⅲ trials (44.37%)and trials involving minors (44.00%), and biological products (34.27%) was higher than that for chemical drugs (7.63%)and traditional Chinese medicines (6.83%). Regarding indications, the DMC application rate of high-risk diseases such as congenital heart disease (100.00%) and pulmonary embolism (60.00%) was markedly higher than that of common cardiovascular diseases such as hypertension (1.69%) and coronary heart disease (7.08%).

Conclusion

The DMC application rate in cardiovascular clinical trials in China remains generally low, but it is more prevalent in high-risk trials.It is recommended to establish differentiated DMC implementation standards based on characteristics of different types of clinical trials, strengthen professional DMC training, and improve the quality control level of clinical trials.

data monitoring committee  /  cardiovascular diseases  /  new drug development  /  clinical trials
陈亚飞, 郑宇, 李鹏博, 刘骏, 于亚南, 王忠. 临床试验数据监查委员会在我国心血管领域新药研发中的应用分析. 世界临床药物, 2025 , 46 (4) : 323 -331 . DOI: 10.13683/j.wph.2025.04.002
Yafei CHEN, Yu ZHENG, Pengbo LI, Jun LIU, Ya'nan YU, Zhong WANG. Analysis of Data Monitoring Committee applications in cardiovascular drug development in China[J]. World Clinical Drug, 2025 , 46 (4) : 323 -331 . DOI: 10.13683/j.wph.2025.04.002
Year 2025 volume 46 Issue 4
45
10
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2025.04.002
  • Receive Date:2024-12-06
  • Online Date:2026-11-09
  • Published:2025-04-10
Article Data
Affiliations
History
  • Received:2024-12-06
Funding
Affiliations
    Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2025.04.002
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT